TechMediaBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Present Fibromyalgia Real-World Data at ISPOR 2026
Tonix Pharmaceuticals (NASDAQ: TNXP) announced a poster presentation at ISPOR 2026 highlighting findings from a retrospective cohort study analyzing U.S. claims data from adults with fibromyalgia between April 2021 and April 2024. The presentation will feature real-world insights related to fibromyalgia treatment, following the FDA approval of TONMYA(R) in August 2025 and its subsequent U.S. commercial launch in November 2025. To view the full press release, visit https://ibn.fm/A3668 Tonix Pharmaceuticals Holding Corp. Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA(TM) (cyclobenzaprine HCl sublingual…